Hikal Limited (IN:HIKAL)
:HIKAL
Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹386.00
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹23.66B
Enterprise Value₹27.05B
Total Cash (Recent Filing)₹138.00M
Total Debt (Recent Filing)₹6.84B
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)-3.96
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.1
Revenue Forecast (FY)₹19.62B
Bulls Say, Bears Say
Bulls Say
Diversified CDMO & Product SalesHikal’s dual model — CDMO services plus manufactured active ingredients for pharma and agro — supports multiple revenue streams and long-term customer relationships. Contract work can convert to recurring manufacturing revenue, while product sales provide scale benefits and cross-market exposure that boost durable cash flow potential.
Manageable LeverageDeclining debt and a modest debt-to-assets ratio improve financial flexibility, lowering refinancing risk and enabling capex or acquisition optionality. A sizable equity base further cushions volatility, making the balance sheet better able to absorb operating swings and support multi-year manufacturing contracts.
Positive Cash GenerationSustained positive operating and free cash flow even during a loss-making year shows the business can convert operations to cash. That supports working capital, debt reduction, and reinvestment in plants or process development—key for a manufacturing/CDMO business where cash funds competitiveness over time.
Bears Say
Profitability DeteriorationThe swing to net losses points to sustained pressure from margin compression or rising operating costs. Persistent negative earnings reduce internal funding for R&D and capacity, weaken covenant headroom, and impair the company’s ability to sustain long-term investments critical for CDMO competitiveness.
Revenue Contraction/instabilityMulti-year inconsistent top-line performance and recent contraction reduce utilization of manufacturing assets, lowering operating leverage. That weakens margin resilience and makes capital allocation harder, since volatile volumes undermine predictable cash flow needed to support long-cycle pharma and agro projects.
Volatile Cash ConversionMaterial swings in free cash flow and prior negative FCF indicate capex or working-capital sensitivity. This volatility raises the risk of future funding needs, possibly forcing higher external financing or capex delays, which can undermine long-term capacity expansion and reliability for large CDMO customers.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹386.00 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹23.66B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Aug 12, 2026 which is in 67 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on May 27, 2026. The company reported ₹1.17 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.17.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.8 which represents an annual dividend yield of 0.58%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹1.17 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.217%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―